Introduction: Plasma cell leukemia (PL) is a rare lymphoproliferative disorder characterized by the monoclonal proliferation of plasma cells in the marrow and blood peripheral. It is defined by a blood plasmacytosis greater than 2 G/l or a plasma cell level greater than 20% of leukocytes. It can be primitive or secondary to multiple myeloma (MM). We reported 3 cases of PL. Observations:Case 1: A 59 years old woman with fever, anemia with 7 g/dl, hyperleukocytosis 9200/mm3, thrombopenia 86 G/l inflammatory biological syndrome with CRP at 129 mg/l, hypercalcemia at 120 mg/l, renal failure with serum creatinine at 35 mg/l, urea at 0.85 g/l and 24-hour proteinuria at 0.98 g/24h. Β2 microglobulin at 10.34 mg/l. The blood smear shows dysmorphic plasma cells at 68% and the bone marrow at 79% of dysmorphic plasma cells. The immunophenotyping of blood cells, the electrophoretic serum protein, shows PL CD38+, secondary of a MM LAMBDA. Case 2: A 65-year-old man with type 2 diabetes presented, right femoral neck, anemia, hyperleukocytosis at 22 G/l, and thrombocytopenia at 99 G/l. There was no hypercalcemia, or kidney failure. The blood smear showed 28% of plasma cells and 9% of blasts. On the myelogram, the marrow was normal richness with significant medullary plasmacytosis (31%) made up of dysmorphic plasma cells. The CT scan showed a settling of the body of D5 with heterogeneous osteocondensation. The patient was transferred to hematology where she was treated with polychemotherapy. The evolution was unfavorable following a death due to malignant hypercalcemia. Case 3: A 62-year-old woman who had a 5-year follow-up of Ig G kappa multiple myeloma was treated with Melphalan, Prednisone, and thalidomide with a therapeutic break for 2 months. She came back to the Internal Medicine department with: severe global dehydration, anemia with externalized bleeding gingivorrhagia, pain in mechanical bones of the ribs, lower limbs, and pelvis, bilateral pneumonia. The biology found hyperleukocytosis at 99 G/l, anemia at 4.7 g/dl, thrombocytopenia at 31 g/l, hypercalcemia at 190 mg/l, renal failure with creatinine at 34 mg/L, and urea at 1.08 g/l, a biological inflammatory syndrome with CRP 294 mg/l. The smeared blood had shown 93% blood plasma cells and immunophenotyping showed CD38+. The patient died before specific treatment for the disease. Conclusion: Plasma cell leukemia is a rare atypical variant, complicating essentially multiple light chain myeloma. She must be
References
[1]
Pagano, L., Valentini, C.G., De Stefano, V., Venditti, A., Visani, G., Petrucci, M.T., et al. (2011) Primary Plasma Cell Leukemia: A Retrospective Multicenter Study of 73 Patients. Annals of Oncology, 22, 1628-1635. https://doi.org/10.1093/annonc/mdq646
[2]
Eddou, H., Mahtat, E., Zahid, H., El Maaroufi, H., Jennane, S., Messaoudi, N., et al. (2013) La leucémie à plasmocytes: à propos de trois cas et revue de la littérature. Annales de Biologie Clinique, 71, 698-702. https://doi.org/10.1684/abc.2013.0888
[3]
Gonsalves, W.I., Rajkumar, S.V., Go, R.S., et al. (2014) Trends in Survival of Patients with Primary Plasma Cell Leukemia: A Population-Based Analysis. Blood, 124, 907-912. https://doi.org/10.1182/blood-2014-03-565051
[4]
Dimopoulos, M.A., Palumbo, A., Delasalle, K.B. and Alexanian, R. (1994) Primary Plasma Cell Leukaemia. British Journal of Haematology, 88, 754-759. https://doi.org/10.1111/j.1365-2141.1994.tb05114.x
[5]
García-Sanz, R., Orfão, A., González, M., et al. (1999) Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics. Blood, 93, 1032-1037. https://doi.org/10.1182/blood.V93.3.1032
[6]
Ramsingh, G., Mehan, P., Luo, J., Vij, R. and Morgensztern, D. (2009) Primary Plasma Cell Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis between 1973 and 2004. Cancer, 115, 5734-5739. https://doi.org/10.1002/cncr.24700
[7]
Tiedemann, R.E., Gonzalez-Paz, N., Kyle, R.A., et al. (2008) Genetic Aberrations and Survival in Plasma Cell Leukemia. Leukemia, 22, 1044-1052. https://doi.org/10.1038/leu.2008.4
[8]
Bladé, J. and Kyle, R.A. (1999) Nonsecretory Myeloma, Immunoglobulin D Myeloma, and Plasma Cell Leukemia. Hematology/Oncology Clinics of North America, 13, 1259-1272. https://doi.org/10.1016/S0889-8588(05)70125-8
[9]
Edvardsen, K., Chen, W., Rucklidge, G., Walsh, F.S., Obrink, B. and Bock, E. (1993) Transmembrane Neural Cell-Adhesion Molecule (NCAM), but Not Glycosyl-Phosphatidylinositol-Anchored NCAM, Down-Regulates Secretion of Matrix Metalloproteinases. Proceedings of the National Academy of Sciences of the United States of America, 90, 11463-11467. https://doi.org/10.1073/pnas.90.24.11463
[10]
Noel, P. and Kyle, R.A. (1987) Plasma Cell Leukemia: An Evaluation of Response to Therapy. The American Journal of Medicine, 83, 1062-1068. https://doi.org/10.1016/0002-9343(87)90942-9
[11]
Colovic, M., Jankovic, G., Suvajdzic, N., Milic, N., Dordevic, V. and Jankovic, S. (2008) Thirty Patients with Primary Plasma Cell Leukemia: A Single Center Experience. Medical Oncology, 25, 154-160. https://doi.org/10.1007/s12032-007-9011-5
[12]
Qi, P.J., et al. (2009) A Retrospective Analysis of Thirty-One Cases of Plasma Cell Leukemia from a Single Center in China. Acta Haematologica, 121, 47-51. https://doi.org/10.1159/000210555
[13]
Usmani, S.Z., Nair, B., Qu, P., et al. (2012) Primary Plasma Cell Leukemia: Clinical and Laboratory Presentation, Gene-Expression Profiling and Clinical Outcome with Total Therapy Protocols. Leukemia, 26, 2398-2405. http://www.ncbi.nlm.nih.gov/pubmed/22508408 https://doi.org/10.1038/leu.2012.107
[14]
Fernández de Larrea, C., Kyle, R.A., Durie, B.G.M., et al. (2012) Plasma Cell Leukemia: Consensus Statement on Diagnostic Requirements, Response Criteria and Treatment Recommendations by the International Myeloma Working Group. Leukemia, 27, 780-791. https://doi.org/10.1038/leu.2012.336
[15]
Pérez-Andrés, M., Almeida, J., Martín-Ayuso, M., et al. (2005) Clonal Plasma Cells from Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma and Plasma Cell Leukemia Show Different Expression Profiles of Molecules Involved in the Interaction with the Immunological Bone Marrow Microenvironment. Leukemia, 19, 449-455. https://doi.org/10.1038/sj.leu.2403647
[16]
Pellat-Deceunynck, C., Barillé, S., Jego, G., et al. (1998) The Absence of CD56 (NCAM) on Malignant Plasma Cells Is a Hallmark of Plasma Cell Leukemia and of a Special Subset of Multiple Myeloma. Leukemia, 12, 1977-1982. https://doi.org/10.1038/sj.leu.2401211
[17]
Kraj, M., Kopec-Szlezak, J., Pogłód, R. and Kruk, B. (2011) Flow Cytometric Immunophenotypic Characteristics of 36 Cases of Plasma Cell Leukemia. Leukemia Research, 35, 169-176. https://doi.org/10.1016/j.leukres.2010.04.021
[18]
Vande Donk, N.W.C.J., Lokhorst, H.M. anderson, K.C. and Richardson, P.G. (2012) How I Treat Plasma Cell Leukemia. Blood, 120, 2376-2389. http://www.ncbi.nlm.nih.gov/pubmed/22837533 https://doi.org/10.1182/blood-2012-05-408682
[19]
Rodriguez, C., Pont, J.C., Gouin-Thibault, I. andrieu, A.G., Molina, T., Le Tourneau, A., et al. (2005) La leucémie à plasmocytes. Annales de Biologie Clinique, 63, 535-539.
[20]
Azais, I., Brault, R. and Debiais, F. (2010) Nouvelles thérapies du myélome. Revue du Rhumatisme, 77, 21-27. https://doi.org/10.1016/j.rhum.2009.09.008
[21]
Mina, R., D’Agostino, M., Cerrato, C., Gay, F. and Palumbo, A. (2017) Plasma Cell Leukemia: Update on Biology and Therapy. Leukemia & Lymphoma, 58, 1538-1547. https://doi.org/10.1080/10428194.2016.1250263